245 related articles for article (PubMed ID: 35214125)
1. Identification of a Quinone Derivative as a YAP/TEAD Activity Modulator from a Repurposing Library.
Lauriola A; Uliassi E; Santucci M; Bolognesi ML; Mor M; Scalvini L; Elisi GM; Gozzi G; Tagliazucchi L; Marverti G; Ferrari S; Losi L; D'Arca D; Costi MP
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214125
[TBL] [Abstract][Full Text] [Related]
2. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
3. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
5. YAP/TAZ-TEAD activity promotes the malignant transformation of cervical intraepithelial neoplasia through enhancing the characteristics and Warburg effect of cancer stem cells.
Li S; Li X; Yang YB; Wu SF
Apoptosis; 2024 Mar; ():. PubMed ID: 38553612
[TBL] [Abstract][Full Text] [Related]
6. Identification of Quinolinols as Activators of TEAD-Dependent Transcription.
Pobbati AV; Mejuch T; Chakraborty S; Karatas H; Bharath SR; Guéret SM; Goy PA; Hahne G; Pahl A; Sievers S; Guccione E; Song H; Waldmann H; Hong W
ACS Chem Biol; 2019 Dec; 14(12):2909-2921. PubMed ID: 31742995
[TBL] [Abstract][Full Text] [Related]
7. Targeting YAP/TAZ-TEAD protein-protein interactions using fragment-based and computational modeling approaches.
Kaan HYK; Sim AYL; Tan SKJ; Verma C; Song H
PLoS One; 2017; 12(6):e0178381. PubMed ID: 28570566
[TBL] [Abstract][Full Text] [Related]
8. Repurposing of Drugs Targeting YAP-TEAD Functions.
Elisi GM; Santucci M; D'Arca D; Lauriola A; Marverti G; Losi L; Scalvini L; Bolognesi ML; Mor M; Costi MP
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30223434
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics simulations study of influence of Tyr422Ala mutation on transcriptional enhancer activation domain 4 (TEAD4) and transcription co-activators complexes.
Niu RJ; Zheng QC; Zhang HX
J Theor Biol; 2019 Jul; 472():27-35. PubMed ID: 30978352
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP-TEAD protein-protein interface 3.
Zhou W; Li Y; Song J; Li C
Anal Biochem; 2019 Dec; 586():113413. PubMed ID: 31479631
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors.
Holden JK; Cunningham CN
Cancers (Basel); 2018 Mar; 10(3):. PubMed ID: 29558384
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of TEAD transcription factors in cancer.
Pobbati AV; Kumar R; Rubin BP; Hong W
Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
[TBL] [Abstract][Full Text] [Related]
13. Leveraging the Fragment Molecular Orbital and MM-GBSA Methods in Virtual Screening for the Discovery of Novel Non-Covalent Inhibitors Targeting the TEAD Lipid Binding Pocket.
Kim J; Jin H; Kim J; Cho SY; Moon S; Wang J; Mao J; No KT
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791396
[TBL] [Abstract][Full Text] [Related]
14. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
[TBL] [Abstract][Full Text] [Related]
15. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
Zagiel B; Melnyk P; Cotelle P
Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis and Evaluation of a Series of 1,5-Diaryl-1,2,3-triazole-4-carbohydrazones as Inhibitors of the YAP-TAZ/TEAD Complex.
Gibault F; Sturbaut M; Coevoet M; Pugnière M; Burtscher A; Allemand F; Melnyk P; Hong W; Rubin BP; Pobbati AV; Guichou JF; Cotelle P; Bailly F
ChemMedChem; 2021 Sep; 16(18):2823-2844. PubMed ID: 34032019
[TBL] [Abstract][Full Text] [Related]
17. Discovery of dioxo-benzo[b]thiophene derivatives as potent YAP-TEAD interaction inhibitors for treating breast cancer.
Son Y; Kim J; Kim Y; Chi SG; Kim T; Yu J
Bioorg Chem; 2023 Feb; 131():106274. PubMed ID: 36434952
[TBL] [Abstract][Full Text] [Related]
18. Validation of chemical compound library screening for transcriptional co-activator with PDZ-binding motif inhibitors using GFP-fused transcriptional co-activator with PDZ-binding motif.
Nagashima S; Maruyama J; Kawano S; Iwasa H; Nakagawa K; Ishigami-Yuasa M; Kagechika H; Nishina H; Hata Y
Cancer Sci; 2016 Jun; 107(6):791-802. PubMed ID: 27009852
[TBL] [Abstract][Full Text] [Related]
19. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
Miesfeld JB; Link BA
Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
[TBL] [Abstract][Full Text] [Related]
20. Identification of FAM181A and FAM181B as new interactors with the TEAD transcription factors.
Bokhovchuk F; Mesrouze Y; Delaunay C; Martin T; Villard F; Meyerhofer M; Fontana P; Zimmermann C; Erdmann D; Furet P; Scheufler C; Schmelzle T; Chène P
Protein Sci; 2020 Feb; 29(2):509-520. PubMed ID: 31697419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
